Publicaciones en colaboración con investigadores/as de Centro Nacional de Biotecnología (145)

2024

  1. Early cortical GABAergic interneurons determine the projection patterns of L4 excitatory neurons

    Science Advances, Vol. 10, Núm. 19

  2. The lack of either IRF9, or STAT2, has surprisingly little effect on human natural killer cell development and function

    Immunology, Vol. 172, Núm. 3, pp. 440-450

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Bacteria-instructed B cells cross-prime naïve CD8+ T cells triggering effective cytotoxic responses

    EMBO Reports, Vol. 24, Núm. 7

  3. Cell type dependent stability and virulence of a recombinant SARS-CoV-2, and engineering of a propagation deficient RNA replicon to analyze virus RNA synthesis

    Frontiers in Cellular and Infection Microbiology, Vol. 13

  4. Dendritic Cell-Mediated Cross-Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS-CoV-2

    Advanced Science, Vol. 10, Núm. 34

  5. Exogenous aralar/slc25a12 can replace citrin/slc25a13 as malate aspartate shuttle component in liver

    Molecular Genetics and Metabolism Reports, Vol. 35

  6. IL-18-induced HIF-1α in ILC3s ameliorates the inflammation of C. rodentium-induced colitis

    Cell Reports, Vol. 42, Núm. 12

  7. Immune synapse formation promotes lipid peroxidation and MHC-I upregulation in licensed dendritic cells for efficient priming of CD8+ T cells

    Nature Communications, Vol. 14, Núm. 1

  8. MYC directly transactivates CR2/CD21, the receptor of the Epstein–Barr virus, enhancing the viral infection of Burkitt lymphoma cells

    Oncogene, Vol. 42, Núm. 45, pp. 3358-3370

  9. NKG2D-CAR memory T cells target pediatric T-cell acute lymphoblastic leukemia in vitro and in vivo but fail to eliminate leukemia initiating cells

    Frontiers in Immunology, Vol. 14

  10. N′-Phenylacetohydrazide Derivatives as Potent Ebola Virus Entry Inhibitors with an Improved Pharmacokinetic Profile

    Journal of Medicinal Chemistry, Vol. 66, Núm. 8, pp. 5465-5483

  11. Optimized vaccine candidate MVA-S(3P) fully protects against SARS-CoV-2 infection in hamsters

    Frontiers in Immunology, Vol. 14

  12. Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates

    Frontiers in Immunology, Vol. 14

  13. The first year of young group of the Spanish Immunology Society: Progress, challenges, and next steps

    European Journal of Immunology

2022

  1. A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection

    Frontiers in Immunology, Vol. 12

  2. Altered CXCR4 dynamics at the cell membrane impairs directed cell migration in WHIM syndrome patients

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 119, Núm. 21

  3. Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice

    npj Vaccines, Vol. 7, Núm. 1

  4. Infusion of haploidentical NKG2D-CAR-TCD45RA- cells in two pediatric patients with advanced relapsed and refractory acute leukemia was safe but achieved no clinical benefits

    Leukemia and Lymphoma

  5. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection

    Frontiers in Immunology, Vol. 13